MOTS-c

MOTS-c is a peptide encoded within mitochondrial DNA rather than nuclear DNA. It is classed as a mitochondrial-derived peptide and is studied as a signaling molecule that carries information between the mitochondria and the rest of the cell. Research interest centers on its role under metabolic stress, where it has been examined for effects on how cells manage energy availability, and it is generally grouped with compounds studied in longevity and metabolic research.

Research describes MOTS-c as translocating to the nucleus when cells are under metabolic stress. Once there, it has been studied for effects on genes that govern metabolic homeostasis, largely through AMPK-associated pathways that help regulate cellular energy balance. One lung injury study reported nuclear translocation dependent on MYH9 and activation of antioxidant genes. These mechanisms come primarily from animal and cell research and have not been confirmed in human trials.

A frequently cited study reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in experimental models. Other work has examined hyperglycemia and insulin resistance in gestational diabetes, pancreatic islet cell senescence and diabetes onset, bone metabolism, lung ischemia-reperfusion injury, sepsis-induced cardiomyopathy, and ovarian cancer progression. Several reviews also discuss its links to stress, metabolism and aging. This work is largely preclinical, and findings should not be taken as established human outcomes.

Human safety data for MOTS-c are limited. The available literature is dominated by animal studies, cell experiments and reviews, and adverse events are not summarized in the cited studies. Long-term effects, interactions and contraindications in humans have not been characterized. Because of these gaps, the safety profile of MOTS-c remains uncertain, and conclusions drawn from preclinical models may not reflect effects in people.

Research protocols have used 500 to 5,000 mcg per administration by the subcutaneous route, three times per week in the morning under fasted conditions. These protocols have been run in 8-week blocks followed by 4 weeks off. This information describes published research practice only and is not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference.